Next Article in Journal
Dendritic Cell-Based and Other Vaccination Strategies for Pediatric Cancer
Previous Article in Journal
Management of Small Bowel Neuroendocrine Tumors
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 11
Issue 9
10.3390/cancers11091386
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Reply to Cancers 2019, 11(9), 1307.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Reply

Reply to Comment on “Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer” Cancers 2019, 11, 596: Markers for Early Detection of Ovarian Cancer

by
Jing Guo
1,2,
Zhen Lu
2,* and
Robert C. Bast, Jr.
2,*
1
Department of Obstetrics and Gynecology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, China
2
Department of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
*
Authors to whom correspondence should be addressed.
Cancers 2019, 11(9), 1386; https://doi.org/10.3390/cancers11091386
Submission received: 29 August 2019 / Accepted: 30 August 2019 / Published: 18 September 2019
Versions Notes
We appreciate Mor et al. [1] correcting our inadvertent oversight of their 2005 paper [2] regarding osteopontin and macrophage inhibitory factor (MIF) as serum biomarkers for ovarian cancer. We had cited their report regarding MIF expression in ovarian cancer by Agarwal and Mor et al in 2007 [3]. We had also cited the first reports regarding osteopontin in serum of ovarian cancer patients by Schorge et al. [4] and in CA125 negative ovarian cancer tissue by Rosen et al. [5].
As we had noted in the manuscript, the novelty of our report deals not with the discovery of new biomarkers for ovarian cancer, but rather their evaluation in large numbers of cases with early stage (I–II) disease. In our study, sera from 76 early stage ovarian cancer patients were tested in the discovery set and from 71 early stage patients in an independent validation set, totaling 147, which is several fold more than in previous reports.
We agree that osteopontin and possibly MIF deserve further evaluation as part of biomarker panels for detection of early stage ovarian cancer.

References

  1. Mor, G.; Rutherford, T.; Alvero, A. Comment on “Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer” Cancers 2019, 11, 596: Markers for Early Detection of Ovarian Cancer. Cancers 2019, 9, 1307. [Google Scholar] [CrossRef] [PubMed]
  2. Mor, G.; Visintin, I.; Lai, Y.; Zhao, H.; Schwartz, P.; Rutherford, T.; Yue, L.; Bray-Ward, P.; Ward, D.C. Serum protein markers for early detection of ovarian cancer. Proc. Natl. Acad. Sci. USA 2005, 102, 7677–7682. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Agarwal, R.; Whang, D.H.; Alvero, A.B.; Visintin, I.; Lai, Y.; Segal, E.A.; Schwartz, P.; Ward, D.; Rutherford, T.; Mor, G. Macrophage migration inhibitory factor expression in ovarian cancer. Am. J. Obstet. Gynecol. 2007, 196, 348.e1–348.e5. [Google Scholar] [CrossRef] [PubMed]
  4. Schorge, J.O.; Drake, R.D.; Lee, H.; Skates, S.J.; Rajanbabu, R.; Miller, D.S.; Kim, J.H.; Cramer, D.W.; Berkowitz, R.S.; Mok, S.C. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin. Cancer Res. 2004, 10, 3474–3478. [Google Scholar] [CrossRef] [PubMed]
  5. Rosen, D.G.; Wang, L.; Atkinson, J.N.; Yu, Y.; Lu, K.H.; Diamandis, E.P.; Hellstrom, I.; Mok, S.C.; Liu, J.; Bast, R.C., Jr. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol. Oncol. 2005, 99, 267–277. [Google Scholar] [CrossRef] [PubMed]

Share and Cite

MDPI and ACS Style

Guo, J.; Lu, Z.; Bast, R.C., Jr. Reply to Comment on “Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer” Cancers 2019, 11, 596: Markers for Early Detection of Ovarian Cancer. Cancers 2019, 11, 1386. https://doi.org/10.3390/cancers11091386

AMA Style

Guo J, Lu Z, Bast RC Jr. Reply to Comment on “Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer” Cancers 2019, 11, 596: Markers for Early Detection of Ovarian Cancer. Cancers. 2019; 11(9):1386. https://doi.org/10.3390/cancers11091386

Chicago/Turabian Style

Guo, Jing, Zhen Lu, and Robert C. Bast, Jr. 2019. "Reply to Comment on “Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer” Cancers 2019, 11, 596: Markers for Early Detection of Ovarian Cancer" Cancers 11, no. 9: 1386. https://doi.org/10.3390/cancers11091386

APA Style

Guo, J., Lu, Z., & Bast, R. C., Jr. (2019). Reply to Comment on “Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer” Cancers 2019, 11, 596: Markers for Early Detection of Ovarian Cancer. Cancers, 11(9), 1386. https://doi.org/10.3390/cancers11091386

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop